NIM
HQL

Nexus Investment Management’s abrdn Life Sciences Investors HQL Stock Holding History

Nexus Investment Management’s Portfolio HQL Stock Details HQL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$640 Hold
32
– – ﹤0.01% 72
2026
Q1 		$521 Buy
+32
New +$535 ﹤0.01% 70
2025
Q3 		– Sell
-1,489
Closed -$19.1K – 76
2025
Q2 		$19.1K Hold
1,489
– – ﹤0.01% 75
2025
Q1 		$27.2K Buy
+1,489
New +$20.2K ﹤0.01% 68

Other funds holding HQL

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $13B AUM 71.84% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
NIM
Needham Investment Management New York $3.33B AUM 163.16% 1-Year Est. Return
FHA
Flagship Harbor Advisors Boston, Massachusetts $2.61B AUM 23.21% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
AAM
Advisors Asset Management Monument, Colorado $6.56B AUM 35.09% 1-Year Est. Return
1WA
180 Wealth Advisors Federal Way, Washington $997M AUM 47.84% 1-Year Est. Return

Nexus Investment Management's HQL Position: Q2 2026 in Review

Nexus Investment Management held its abrdn Life Sciences Investors (HQL) position steady in Q2 2026 at 32 shares worth $640. The position accounts for ﹤0.01% of the portfolio, ranked #72.

Nexus Investment Management first reported a position in HQL in Q1 2025 and has held it in 4 quarters since. The position peaked at $27.2K in Q1 2025. 83 funds tracked by Wall St. Rank hold HQL as of Q2 2026.

  • Nexus Investment Management held 32 shares of abrdn Life Sciences Investors worth $640 as of Q2 2026.
  • Nexus Investment Management left its abrdn Life Sciences Investors share count unchanged in Q2 2026.
  • abrdn Life Sciences Investors made up ﹤0.01% of Nexus Investment Management's portfolio in Q2 2026, its #72 holding.
  • Nexus Investment Management first reported a position in abrdn Life Sciences Investors in Q1 2025 and has held it in 4 quarters since.
  • Nexus Investment Management's abrdn Life Sciences Investors position peaked at $27.2K in Q1 2025.
  • 83 funds tracked by Wall St. Rank held abrdn Life Sciences Investors as of Q2 2026.

Based on Nexus Investment Management's 13F filing for Q2 2026, filed 20 Jul 2026.